相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
Jolanta M. Siller-Matula et al.
AMERICAN HEART JOURNAL (2009)
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects
N. A. Farid et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel
Yumi Nishiya et al.
DRUG METABOLISM AND DISPOSITION (2009)
Treatment of Acute Myocardial Infarction in Patients with Stimulant ST-segment Elevation
Frans Van de Werf et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention
Spencer B. King et al.
CIRCULATION (2008)
The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance
K. A. Kim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2
Eric T. Williams et al.
DRUG METABOLISM AND DISPOSITION (2008)
Comparison of Human Cytochrome P450 Inhibition by the Thienopyridines Prasugrel, Clopidogrel, and Ticlopidine
Katsunobu Hagihara et al.
DRUG METABOLISM AND PHARMACOKINETICS (2008)
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS
Makoto Takahashi et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention
Elliott M. Antman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin
Martine Gilard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor
I. Algaier et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
Nagy A. Farid et al.
PHARMACOTHERAPY (2008)
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation
Frans Van de Werf et al.
EUROPEAN HEART JOURNAL (2008)
Prasugrel achieves greater and faster P2Y(12) receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Cytochrome P4502C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
Betti Giusti et al.
PHARMACOGENETICS AND GENOMICS (2007)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
Christopher D. Payne et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status
Govinda J. Weerakkody et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
A. Sugidachi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The disposition of prasugrel, a novel thienopyridine, in humans
Nagy A. Farid et al.
DRUG METABOLISM AND DISPOSITION (2007)
Optimizing platelet P2Y12 inhibition for patients undergoing PCI
Steven Steinhubl et al.
CARDIOVASCULAR DRUG REVIEWS (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
John T. Brandt et al.
AMERICAN HEART JOURNAL (2007)
Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method
Enaksha R. Wickremsinhe et al.
DRUG METABOLISM AND DISPOSITION (2007)
Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry
Nagy A. Farid et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2007)
Disposition and metabolic fate of prasugrel in mice, rats, and dogs
R. L. Smith et al.
XENOBIOTICA (2007)
Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol
Man Tang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Onset and offset of platelet inhibition after high-dose Clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers
Matthew J. Price et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
Jung-Won Suh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor:: A multiple-dose study in healthy humans
Nobuko Matsushima et al.
PLATELETS (2006)
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor:: A single ascending dose study in healthy humans
Fumitoshi Asai et al.
PLATELETS (2006)
The human intestinal cytochrome P450 pie
MF Paine et al.
DRUG METABOLISM AND DISPOSITION (2006)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
T Jernberg et al.
EUROPEAN HEART JOURNAL (2006)
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
JLF Rehmel et al.
DRUG METABOLISM AND DISPOSITION (2006)
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
T Cuisset et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry
RVS Nirogi et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2006)
Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status
I Ieiri et al.
PHARMACOGENETICS AND GENOMICS (2005)
Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention -: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial
SD Wiviott et al.
CIRCULATION (2005)
Effect of clopidogrel and ticlopidine on cytochrome P4502B6 activity as measured by bupropion hydroxylation
M Turpeinen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting
DJ Angiolillo et al.
THROMBOSIS RESEARCH (2005)
Determination of the carboxylic acid metabolite of clopidogrel in human plasma by liquid chromatography-electrospray ionization mass spectrometry
A Mitakos et al.
ANALYTICA CHIMICA ACTA (2004)
Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: Role of peroxidases, cytochromes P450, and monoamine oxidases
DK Dalvie et al.
DRUG METABOLISM AND DISPOSITION (2004)
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
S Matetzky et al.
CIRCULATION (2004)
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine
T Richter et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Identification of the active metabolite of ticlopidine from rat in vitro meta bolites
K Yoneda et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro
M Turpeinen et al.
DRUG METABOLISM AND DISPOSITION (2004)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction
WC Lau et al.
CIRCULATION (2003)
Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke
TL Lenz et al.
CLINICAL PHARMACOKINETICS (2003)
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
TA Clarke et al.
DRUG METABOLISM AND DISPOSITION (2003)
Structure and stereochemistry of the active metabolite of clopidogrel
JM Pereillo et al.
DRUG METABOLISM AND DISPOSITION (2002)
Proton pump inhibitors - differences emerge in hepatic metabolism
KEL McColl et al.
DIGESTIVE AND LIVER DISEASE (2002)
Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P4502C19
NT Ha-Duong et al.
BIOCHEMISTRY (2001)
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement
I Muller et al.
HEART (2001)
Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
Y Cadroy et al.
CIRCULATION (2000)
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
A Sugidachi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
分享论文
